by Justin Deschamps,
The Coronavirus outbreak has reportedly claimed 17 lives and is being widely covered by mainstream newsletters. Conspiracy realists-are hot on the case, searching the internet for anything strange—and they weren’t disappointed. There were 19 different Coronavirus patents that were filed well before the outbreak started last week—some going back to 1984. Is this proof of a false flag or manufactured outbreak?
Historically, the Deep State and big pharma seem to find a new virus, or two, every year to drum up an ocean of fear, paranoia, and anxiety. Do you remember SARS, ZIKA, and Avian Flu?
Is there a precedent that drug companies make gobs of money from health scares like this?
In her 1994 book, Disease Mongers, Lynn Prayers makes the case that the for-profit healthcare business, from food to doctors, to insurance, to drug companies, work hand-in-glove to ensure big profits.
Related Coronavirus Deaths Double Overnight To 17, Suspected Case Identified In St. Petersburg
How?
By creating fear around a health issue so you go out and buy what they’re selling.
How do they do this?
Through mass media.
Book Big Pharma, Big Agri, Big Conspiracy: A New World Order Spin on Drugs and GMOs
For example, Science Daily, which I argue is propaganda outlet for the Deep State, regularly posts man-made climate change and anti-vax propaganda (with glaring bias), had three articles about Coronavirus posted within 2 hours of each other (here, here, and here).
As a long-time researcher and watcher of the powers that be my gut tells me this smells fishy.
I was alerted to the fact Corona Patents were filed before the outbreak took place last week.
Here’s the list of 19 I discovered, courtesy of usahitman.com:
Below is a quick list of patents which deal with this ‘new’ coronavirus. Well there is a pretty recent patent as of July 4th, 2019 with this coronavirus. We know how most of these viruses are lab created and this provides some more reach or information to research!
- CORONAVIRUS PROTEINS AND ANTIGENS Publication number: 20160339097 Abstract: Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhea virus (PEDV) or porcine delta coronavirus (PDCoV). Also disclosed are embodiments of a composition comprising the coronavirus proteins and antigens, and embodiments of a method of using such a composition. Applications for the composition include, but are not limited to, use in the preparation of antibodies against the proteins and antigens, use as reference markers for coronavirus proteins, and/or use in an immunogenic composition, such as in a vaccine composition. Type: Application Filed: August 4, 2016 Publication date: November 24, 2016 Applicant: MJ Biologics, Inc. Inventor: Byoung-Kwan Kim
- CORONAVIRUS PROTEINS AND ANTIGENS Publication number: 20190202868 Abstract: Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhea virus (PEDV) or porcine delta coronavirus (PDCoV). Also disclosed are embodiments of a composition comprising the coronavirus proteins and antigens, and embodiments of a method of using such a composition. Applications for the composition include, but are not limited to, use in the preparation of antibodies against the proteins and antigens, use as reference markers for coronavirus proteins, and/or use in an immunogenic composition, such as in a vaccine composition. Type: Application Filed: March 15, 2019 Publication date: July 4, 2019 Applicant: Phibro Animal Health Corporation Inventor: Byoung-Kwan Kim
- Coronavirus proteins and antigens Patent number: 10280199 Abstract: Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhea virus (PEDV) or porcine delta coronavirus (PDCoV). Also disclosed are embodiments of a composition comprising the coronavirus proteins and antigens, and embodiments of a method of using such a composition. Applications for the composition include, but are not limited to, use in the preparation of antibodies against the proteins and antigens, use as reference markers for coronavirus proteins, and/or use in an immunogenic composition, such as in a vaccine composition. Type: Grant Filed: August 4, 2016 Date of Patent: May 7, 2019 Assignee: Phibro Animal Health Corporation Inventor: Byoung-Kwan Kim
- Vaccine compositions and methods of treating coronavirus infection Publication number: 20060286124 Abstract: The present disclosure relates to compositions and methods for treating or preventing coronavirus infections. For example, compositions are provided that comprise a coronavirus S protein or N protein, fragment, or variant thereof, capable of eliciting a protective humoral and/or cell-mediated immune response, which compositions are useful for treating or preventing infection by coronavirus, such as the causative agent of SARS. Also, coronavirus S protein and N protein immunogen compositions are provided that include an adjuvant, such as Proteosome or Protollin, which may be used for treating or preventing infection caused by a coronavirus, such as a SARS coronavirus. Type: Application Filed: June 30, 2005 Publication date: December 21, 2006 Applicant: ID Biomedical Corporation of Quebec Inventors: David Burt, Mark Reddish, Mary Hu, George Lowell, David Jones
- Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMP-dependent kinase and a target for SARS therapy Publication number: 20050276818 Abstract: The present invention relates to novel methods for identifying antiviral agents which selectively interfere with viral proteins that cause the unique infectivity activity of the SARS-coronavirus in comparison to other non-SARS strains of coronavirus. In particular, the present invention relates to screening assays that identify agents which selectively inhibit cyclic-AMP dependent protein kinase activity of the SARS-coronavirus ORF3. The present invention also relates to screening assays that identify agents which selectively inhibit the interaction between SARS-coronavirus cyclic-AMP dependent protein kinase and a calcium dependent targeting molecule. Therefore the agents identified using the assays of the invention may have utility as antiviral agents. The present invention also relates to treatments for sever acute respiratory syndrome caused by a coronavirus, and particularly to treatments that affect the infectivity activity of the SARS-coronavirus. Type: Application Filed: May 17, 2005 Publication date: December 15, 2005 Inventors: Adam Godzik, Sergey Sikora
- Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMP-dependent kinase and a target for SARS therapy Patent number: 7504205 Abstract: The present invention relates to novel methods for identifying antiviral agents which selectively interfere with viral proteins that cause the unique infectivity activity of the SARS-coronavirus in comparison to other non-SARS strains of coronavirus. In particular, the present invention relates to screening assays that identify agents which selectively inhibit cyclic-AMP dependent protein kinase activity of the SARS-coronavirus ORF3. The present invention also relates to screening assays that identify agents which selectively inhibit the interaction between SARS-coronavirus cyclic-AMP dependent protein kinase and a calcium dependent targeting molecule. Therefore the agents identified using the assays of the invention may have utility as antiviral agents. The present invention also relates to treatments for sever acute respiratory syndrome caused by a coronavirus, and particularly to treatments that affect the infectivity activity of the SARS-coronavirus. Type: Grant Filed: May 17, 2005 Date of Patent: March 17, 2009 Assignee: The Burnham Institute Inventors: Adam Godzik, Sergey Sikora
- Inactivated canine coronavirus vaccine Patent number: 4567042 Abstract: An efficacious parenterally administered inactivated canine coronavirus vaccine which provides systemic, humoral protection and also protection of the intestinal tract in dogs from infection by virulent canine coronavirus is produced. A method for propagation of the canine coronavirus and its attenuation and a method of evaluating the effectiveness of a canine coronavirus vaccine in canines is also disclosed. Type: Grant Filed: June 7, 1984 Date of Patent: January 28, 1986 Assignee: American Home Products Corporation Inventors: William M. Acree, Bobby Edwards, John W. Black
- CANINE RESPIRATORY CORONAVIRUS (CRCV) SPIKE PROTEIN, POLYMERASE AND HEMAGGLUTININ/ESTERASE Publication number: 20090081780 Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (e.g., Quebec and LY138) and human coronavirus strain OC43. Type: Application Filed: September 26, 2008 Publication date: March 26, 2009 Applicant: The Royal Veterinary College Inventors: John Brownlie, Victoria Jane Chalker, Kerstin Erles
- PEPTIDE COMPOUNDS FOR DETECTING OR INHIBITING SARS CORONAVIRUS AND APPLICATION THEREOF Publication number: 20100304363 Abstract: Disclosed herein are peptide compounds and the application thereof to the detection and inhibition of SARS coronavirus. Composed of dipeptides, the compounds for detecting and inhibiting SARS coronavirus can be readily synthesized and produced at low cost. In addition, they can be stored safely for a long period of time. The dipeptide compounds are useful as inhibitors of SARS coronavirus as well as acting as excellent capturing materials of SARS coronavirus. Type: Application Filed: May 26, 2010 Publication date: December 2, 2010 Applicant: ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE Inventors: Soo-Hyung LEE, Hyo-Bong Hong, Tao-Wan Kim, Myung-Ae Chung, Sung-Woo Sohn, Seoung-Min Yoo
- Canine Respiratory Coronavirus (Crcv) Spike Protein, Polymerase and Hemagglutinin/Esterase Publication number: 20070248616 Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (e.g. Quebec and LY138) and human coronavirus strain OC43. The CRCV spike, polymerase and hemagglutinin/esterase cDNA and protein partial sequences are listed in FIGS. (1) to (4), (13) and (14). Type: Application Filed: July 1, 2003 Publication date: October 25, 2007 Inventors: John Brownlie, Victoria Chalker, Kerstin Erles
- Canine respiratory coronavirus (CRCV) spike protein Patent number: 7981427 Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (e.g., Quebec and LY138) and human coronavirus strain OC43. Type: Grant Filed: September 26, 2008 Date of Patent: July 19, 2011 Assignee: The Royal Veterinary College Inventors: John Brownlie, Victoria Jane Chalker, Kerstin Erles
- Methods and compositions for infectious cDNA of SARS coronavirus Publication number: 20060240530 Abstract: The present invention provides a cDNA of a severe acute respiratory syndrome (SARS) coronavirus, recombinant SARS coronavirus vectors, and SARS coronavirus replicon particles. Also provided are methods of making the compositions of this invention and methods of using the compositions as immunogens and/or vaccines and/or to express heterologous nucleic acids. Type: Application Filed: January 19, 2006 Publication date: October 26, 2006 Inventors: Ralph Baric, Rhonda Roberts, Boyd Yount, Kristopher Curtis
- Compositions and methods for detecting severe acute respiratory syndrome coronavirus Publication number: 20050095582 Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus. Type: Application Filed: November 3, 2003 Publication date: May 5, 2005 Applicants: Diagnostic Hybrids, Inc., Health Research Incorporated Inventors: Laura Gillim-Ross, Jill Taylor, David Scholl, David Wentworth, Joseph Jollick Compositions and Methods for Detecting Severe Acute Respiratory Syndrome Coronavirus Publication number: 20080076115 Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus. Type: Application Filed: November 3, 2004 Publication date: March 27, 2008 Inventors: David R. Scholl, Joseph D. Jollick, Laura Gillim-Ross, Jill Taylor, David E. Wentworth
- Compositions And Methods For Detecting Severe Acute Respiratory Syndrome Coronavirus Publication number: 20110223659 Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus. Type: Application Filed: December 7, 2010 Publication date: September 15, 2011 Inventors: David R. Scholl, Joseph D. Jollick, Laura Gillim-Ross, Jill Taylor, David E. Wentworth
- Ribozyme to cleave coronavirus gene Publication number: 20100273997 Abstract: Provided is a ribozyme to cleave a coronavirus gene and a therapeutic agent for a coronavirus infectious disease. A common base sequence in coronaviruses such as SARS-CoV and MHV was searched to design a ribozyme including a base sequence complementary thereto. Moreover, a therapeutic agent for a coronavirus infectious disease including such ribozyme was obtained. Type: Application Filed: August 9, 2006 Publication date: October 28, 2010 Inventors: Noboru Fukuda, Takahiro Ueno, Akiko Fukushima, Kazumichi Kuroda
- Compositions and methods for treating coronavirus infection and SARS Publication number: 20050002901 Abstract: The present invention provides methods of treating a coronavirus infection, and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from a coronavirus infection. The present invention further provides methods of reducing the risk that an individual will develop a pathological coronavirus infection, that has clinical sequelae. The present invention further provides methods of reducing the risk that an individual will develop SARS. The present invention further provides methods of treating SARS. The methods generally involve administering a therapeutically effective amount of a Type I or Type III interferon receptor agonist and/or a Type II interferon receptor agonist for the treatment of a coronavirus infection. Type: Application Filed: March 30, 2004 Publication date: January 6, 2005 Inventor: Lawrence Blatt
- FUSION PROTEINS OF RECOMBINANT SARS CORONAVIRUS STRUCTURAL PROTEINS, THEIR PRODUCTION AND USES Publication number: 20100150923 Abstract: Fusion proteins of recombinant SARS coronavirus structural proteins, their production and uses are provided. An optimized SARS coronavirus S protein gene which can be highly expressed in the mammalian cell strains and SARS coronavirus S protein variants comprising deletion, modification or mutation amino acids 318-510 corresponding to SARS coronavirus S protein are also provided. Type: Application Filed: June 13, 2006 Publication date: June 17, 2010 Applicant: Chinese Academy of Medical Sciences, Institute of Basic Medical Sciences Inventors: Chengyu Jiang, Feng Guo, Shuan Rao, Bing Guan, Yi Huan, Peng Yang
- Civet animal model system for Severe Acute Respiratory Syndrome (SARS) coronavirus infection and uses thereof Publication number: 20060123499 Abstract: The present invention is directed towards the use of the masked palm civet Paguma larvata (“civet”) as an animal model system for SARS, and is based on the novel demonstration of the present invention that civets may be infected with exogenous coronavirus, and that such infection produces SARS-like symptoms in these infected animals. The present invention is directed to a civet model system for the study of the infection, replication, and clinical effects of exogenously introduced human SARS-CoV coronavirus strains, civet SARS-CoV-like coronavirus strains, or variants or derivatives thereof, and to the development of vaccines (or other methods of prevention) or treatment of infection or transmission to other civets or humans of these human SARS-CoV coronavirus strains, civet SARS-CoV-like coronavirus strains, or variants or derivatives thereof. Type: Application Filed: December 6, 2004 Publication date: June 8, 2006 Inventors: Donglai Wu, Xiangang Kong, Qingwen Meng, Yonggang Liu, Yuntao Guan, Xunnan Yin, Mouping Wang, Changwen Li, Ming Liao, Chao-an Xin, Jinding Chen, Changchun Tu, Hua Xuan, Yedong Yu
- METHODS AND COMPOSITIONS FOR CORONAVIRUS DIAGNOSTICS AND THERAPEUTICS Publication number: 20160238601 Abstract: The present invention provides methods and compositions for detecting a coronavirus in a sample and identifying the subgroup of the coronavirus in the sample. Type: Application Filed: October 14, 2014 Publication date: August 18, 2016 Inventors: Ralph Baric, Sudhakar Agnihothram, Boyd Yount
Here’s another coronavirus patent found on Google.
At first glance, it looks pretty damning, doesn’t it?
But before we go jumping to conclusions, we should exercise some critical thinking and discernment.
What’s the claim?
Well, the implication is that… if the coronavirus was patented before the outbreak, was the outbreak a manufactured event? Did they intentionally release this virus?
To assess a claim, you need to know what the claim is saying. You need to know what the things are that it talks about.
Related Amazing Coincidence! Coronavirus VACCINE Just Announced
What is a coronavirus?
Third Eye (Healing Tonic): Pineal Gland Decalcifier, Powerful Nootropic, Supports Pineal Function, Melatonin Regulation, Dream Activation, (Handcrafted in small batches) the perfect blend of mushrooms and herbs made from scratch! Use Promo Code SITS20 for 20% discount on this and other products in your order. Third Eye, on Sale NOW!
According to the CDC,
Human coronaviruses are common throughout the world. Seven different coronaviruses, that scientists know of, can infect people and make them sick. Some human coronaviruses were identified many years ago and some have been identified recently. Human coronaviruses commonly cause mild to moderate illness in people worldwide. Two newer human coronaviruses, MERS-CoV and SARS-CoV, have been known to frequently cause severe illness.
Scientifically, coronavirus is a classification of viruses, within what’s called a taxonomy, or an arbitrary way of categorizing a set of data.
They are called coronaviruses because of their halo-like shape seen under an electron microscope.
What does this mean?
It means that the patents of coronavirus were likely for other strains—not the Wuhan strain.
The current name given to coronavirus at hand is 2019-nCoV.
As far as I can tell, there is no confirmation that the strain causing the outbreak is one of the ones patented.
At this point, it’s highly likely the patent proof cited above doesn’t apply—it might be for coronaviruses, but we don’t know for sure if it’s the Wuhan strain.
Does that mean there is something suspicious potentially happening too?
You bet.
Coronavirus is sweeping the planet. Guard against VIRUSES and Pathogens with the proven Colloidal Silver formula, Spartan Silver.
At the very least, it’s likely the media will sensationalize this and make drug companies piles of cash in the process.
And more damning evidence might surface soon.
Keep your eyes peeled.
– Justin
The preceding is a Stillness in the Storm original creation. Please share freely.
About The Author
Justin Deschamps has been a truth seeker all his life, studying physics, psychology, law, philosophy, and spirituality, and working to weave these seemingly separate bodies of information into a holistic tapestry of ever expanding knowledge. Justin is a student of all and a teacher to some, sharing what he has discovered with those who are ready and willing to take responsibility for making the world a better place. The goal of his work is to help himself and others become better truth-seekers, and in doing so, form a community of holistically minded individuals capable of creating world healing projects for the benefit of all life—what has been called The Great Work. Check out his project Stillness in the Storm to find some of his work. Follow on Twitter @sitsshow, Facebook Stillness in the Storm, and minds.com.
Like our work? Support this site with a contribution via Paypal, cryptocurrencies, or P
This article appeared first on Stillness in the Storm.
Not sure how to make sense of this? Want to learn how to discern like a pro? Read this essential guide to discernment, analysis of claims, and understanding the truth in a world of deception: 4 Key Steps of Discernment – Advanced Truth-Seeking Tools.
Stillness in the Storm Editor’s note: Did you find a spelling error or grammatical mistake? Send an email to corrections@stillnessinthestorm.com, with the error and suggested correction, along with the headline and url. Do you think this article needs an update? Or do you just have some feedback? Send us an email at sitsshow@gmail.com. Thank you for reading.
Source:
https://www.cdc.gov/coronavirus/about/symptoms.html
https://ui.adsabs.harvard.edu/abs/2005Sci…309.1864L/abstract
Facebook flagged this as False information as I tried to share it. It said I could post anyway. We shall see. They are censoring big time to keep the truth hidden.
Funny. They probably didn’t read the article. It clearly says that the idea the coronavirus that is spreading around was released has no evidence to support it.
But the chatter in Whatsapp is that China found 8 bio-hazard canisters buried in the backyard of the deserted US consulate in Wuhan. If true that the US released the nCov in Wuhan, this is a war crime.
Yes, truly a war crime and beyond.
Wednesday May 20, 2020
Suggest you read: https://en.wikipedia.org/wiki/Moderna
Add to that, read Principles of Biochemistry, Albert L. Lehninger, The John Hopkins University School of Medicine, Worth Publishers, Inc.
Chapter 8: Proteins: Covalelent Structures and Biological Functions & specifically “The Immune Response Can Detect Differences betweeen Homologous Proteins
Chapter 17: Incomplete Reduction of Oxygen Causes Cell Injury (more specifically cell membranes due to production of H2O2 (hydrogen peroxide) and superoxide radical (shown as :O2-) which react toxically to the unsaturated fatty acid components of membrane lipid cells thus damaging membrane structure … and further on regarding toxic quinone maskede in hydroquinone by hdrogen peroxide used by an insect. Further, realize that malaria treatments used hydroxy chloro quinone being taken by President Trump on advice from his physicians as a preventative, even though side-effects are known and there is no evidence whatsoever proving the effectiveness fro “Corona viruses”.
Chapter 30: More about Genes, Repair , Mutation, Recombination and Cloning and specifically “DNA is Constantly Subject to Damage” as well as “Ultraviolet Can be Excised and Repaired” and “spontaneous Deamination to Uracil Can be Repaired, further “Damage by External Chemical Agents Can Also be Repaired” etcetera with a discussion of Antigen and Antibody specifically “an antigen of a foreign invader can bind to and stimulate the growth and division of one specific type of immunocyte, to yield a unique line or clone of cells, all identical”.
Furthermore: Genes from Different Organisms Can be Artificially Recombined, Plasmids and Phase Lambda are Vectors for Introducing Foreign Genes into Bacteria; and
Recombinant DNA Research May Have Many Practical Applications.
Then do a Search of the USPTO patent applications regarding Corona Virus-19 and its impact on not only the USPTO but “around the world”.
More specifically an article published in The Jerusalem Post regarding Pluristem usage and the “success rate” on a limited number of “patients” together with all provisional patent applications as well as issued patents relevant to “Corona viruses” as a “classification”.
Please also realize that USPTO Statutory Patent Law does not permit patents for “HUMAN LIFE”, yet the US FDA required that one own stem cells (adult) undergo the same standards of clinical proof as applicable to “Pharmaceuticals”. Google has been openly publishing such results from worldwide clinical laboratory locations. So have others off-shore that require rigorous “clinical pr0of”.
Sincerely, with best regards,
s/LANDALEIP, Inc dba A Patent Agent/ .
There are “obvious errors” that do not detract from the overall message.
s/LANDALEIP/ aka s/LANDALEIP, Inc dba A Patent Agent/
Ph.D. and B.Sc. (First Class Honours), Organic Chemistry, Commonwealth Scholarships, University of Sydney, Australia (one of 7 global universities in Australia);
Robert A. Welch Foundation Postdoctoral Scholar, “Computers and Chemistry” with Professor Michael James, S. Dewar (the First ever Robert A. Welch Foundation Professor of Chemistry in 1974), University of Texas at Austin, Texas, U.S.A.
U.S. Registered Patent Agent licensed by the USPTO and proudly a member of the Patent Bar of the United States Patent & Trademark Office (USPTO);
Formerly and proudly outsourced to the U.S. Navy;
Employee of Hewlett-Packard, Inc. as a Supply Chain Engineer sent overseas to “train HP employees” and interact with HP Suppliers, although initially hired as an adhesives and materials expert, than worked as an ink chemist;
Employee of the Hysol Aerospace Division of the Dexter Corporation, David Coffin Award for Innovation and Chemist of the Year 1983 with “friends” who were initially clients, and recommended me to write a Chapter in Elsevier Developments in Reinforced Plastics – 5 edited by G. Pritchard as a Consultant, Monterey, California, U.S.A. One of my friends/colleagues who had been with Lockheed and Boeing has very sadly passed away leaving a widow and 2 grown children;
Employee of the third largest Textile Corporation in the USA (originally Deering-Milliken and then became Milliken Corporation, which has filed thousands of patent applications, although Roger Milliken who was originally from the Northern, U.S.A. has passed away and is buried in South Carolina; and
MUCH MORE.